Latest Intraocular pressure Stories

Oct. 26 scientific program highlightsA first-time finding of intraocular pressure increases in patients with no personal or family history of glaucoma following anti-VEGF treatment for wet age-related macular degeneration (AMD), and a report on a simple, low-cost method that could revolutionize vision screening and treatment in developing countries, are highlights of today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American...

LAWRENCEVILLE, N.J., Aug. 19 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic...

The overall number of glaucoma surgical procedures appears to be increasing, but payments by Medicare for the procedures have been decreasing, according to a report in the July issue of Archives of Ophthalmology, one of the JAMA/Archives journals.Glaucoma is one of the leading causes of blindness worldwide and currently affects more than 2 million people in the United States, according to background information in the article. "Management and treatment of glaucoma can be costly, and it...

NEW YORK, MONTREAL and SAN DIEGO, CA, July 7 /PRNewswire-FirstCall/ - Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT), and Ocular Therapeutics Inc. of San Diego California, announced that Ocular Therapeutics has signed non-disclosure agreements with two of the largest pharmaceutical firms in the world. These unnamed companies are interested in a new treatment approach in the largest of the ophthalmic markets. High Interest in a New Approach to Glaucoma Treatment...

The July issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes two studies that may influence clinical treatment of serious eye conditions. One study reports on silent cerebral infarcts (SCI) incidence and visual field loss in patients with normal-tension glaucoma; the other correlates inflammation biomarkers with corneal transplant rejection in herpes simplex patients.Silent Cerebral Infarcts: Risk Factor for Visual Field Loss as Well as for Stroke?Health...

LAWRENCEVILLE, N.J., April 6 /PRNewswire/ -- In a recent survey of ophthalmologists across the nation, virtually all (97%) believe preservative-free glaucoma medications can enhance the ocular comfort of glaucoma patients, while 86% believe that preservative-free glaucoma medications can enhance patient quality of life. Nine out of ten (89%) feel there are not enough preservative-free glaucoma medications available, and nearly half (47%) do not know a preservative-free beta-blocker is...

Leading Glaucoma Experts are Working Together to Provide Tips to Help Prevent Vision Loss as Glaucoma Prevalence is Rising Rapidly Across the Globe NEW YORK, March 12 /PRNewswire/ -- On the second annual World Glaucoma Day (March 12), leading global glaucoma experts are working together to help educate patients diagnosed with glaucoma and those who may be at risk for the condition. Glaucoma is a worldwide epidemiological challenge affecting approximately four percent of the global...

LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the TIMOPTIC(R) product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from...

- Clinical Performance Indicates a 40% Reduction of Intraocular Pressure at Two Years - WALTHAM, Mass., Feb. 19 /PRNewswire/ -- SOLX, Inc. announced today that it has surpassed 1000 implantation procedures with its proprietary SOLX Gold Shunt(R), a drainage device that reduces intraocular pressure (IOP) for the treatment of glaucoma. "This is a significant milestone," said Doug Adams, President and Founder of SOLX, "as it validates the importance of the Gold Shunt in the treatment of...

The New York Eye and Ear Infirmary Joins International Observance To Draw Attention To "The Sneak Thief of Sight" NEW YORK, Feb. 12 /PRNewswire-USNewswire/ -- In an effort to combat one of the leading causes of blindness worldwide, the World Glaucoma Association and the World Glaucoma Patient Organization have set March 12, 2009, as the second annual World Glaucoma Day. The day will be marked by awareness and educational events organized by eye care institutions and local patient support...